Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Nasdaq climbs over 1% as AI-linked stocks recover ahead of key earnings
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month highs with Hormuz crossings, Russian sanctions waiver in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- Cerebras Systems falls as TD Cowen cuts price target
- Glass House Brands posts Q3 revenue of $56.8M, board member exits
- Nasdaq climbs over 1% as AI-linked stocks recover ahead of key earnings
- Marvell Technology shares rise on analyst support
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 3, 2022 7:30 AM EDTARCALYST® (rilonacept) net revenue of $27.0 million in Q2 2022
ARCALYST full-year 2022 net revenue expected to be $115 - $130 million
 Upfront and near-term proceeds of $100 million expected from vixarelimab global license agreement
Cash reserves after the close of the vixarelimab global license agreement expected to fund operations into at least 2025 Conference call and webcast scheduled for 8:30 am ETÂ todayÂ
HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) --... More



